Trial Profile
NIK-333 (Peretinoin) Phase III Study Investigation of the Efficacy and Safety to Suppress Recurrence of Hepatitis C Virus (HCV)-Positive Hepatocellular Carcinoma (HCC), Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jun 2022
Price :
$35
*
At a glance
- Drugs Peretinoin (Primary)
- Indications Hepatitis C; Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Kowa Pharmaceutical
- 26 Nov 2020 Status changed from active, no longer recruiting to completed.
- 23 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 23 Jul 2012 New trial record